TABLE 2

Time Point Response: Patients with Nontarget Disease Only (RECIST 1.0 and 1.1) (8,145)

Nontarget lesionsNew lesionsOverall response
CRNoCR
Non-CR/non-PDNoNon-CR/non-PD*
Not all evaluatedNoNE
Unequivocal PDYes or noPD
AnyYesPD

  • ↵* “Non-CR/non-PD” is preferred over “stable disease” for nontarget disease. Because stable disease is increasingly used as endpoint for assessment of efficacy in some trials, it is not advisable to assign this category when no lesions can be measured.

  • CR = complete response; PD = progressive disease; NE = not evaluable.